Combining a NY-ESO-1 protein vaccine with the liposome-encapsulated chemotherapeutic drug doxorubicin and the demethylation agent Decitabine enhanced the specific humoral and CD8+ immune responses in 67 and 50% of patients with relapsed epithelial ovarian cancer (105). Here, CD8A is linked to ovarian carcinoma.